Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of CreaVax-RCC Inj. versus sorafenib in metastatic renal cell carcinoma
KCT0000101Phase 3Recruiting
- Sponsor
- JW CreaGene
- Start
- Jun 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CreaVax-RCC in metastatic renal cell carcinoma (mRCC), sponsored by JW CreaGene. Started Jun 2008; status: recruiting.
02
Drugs
CreaVax-RCC
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on KCT0000101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000101.